HomeCompareCLGUF vs ABBV

CLGUF vs ABBV: Dividend Comparison 2026

CLGUF yields 2336.45% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLGUF wins by $42604535760.32M in total portfolio value
10 years
CLGUF
CLGUF
● Live price
2336.45%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42604535760.42M
Annual income
$39,296,041,752,408,910.00
Full CLGUF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CLGUF vs ABBV

📍 CLGUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLGUFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLGUF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLGUF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLGUF
Annual income on $10K today (after 15% tax)
$198,598.13/yr
After 10yr DRIP, annual income (after tax)
$33,401,635,489,547,576.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CLGUF beats the other by $33,401,635,489,526,520.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLGUF + ABBV for your $10,000?

CLGUF: 50%ABBV: 50%
100% ABBV50/50100% CLGUF
Portfolio after 10yr
$21302267880.26M
Annual income
$19,648,020,876,216,840.00/yr
Blended yield
92.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CLGUF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLGUF buys
0
ABBV buys
0
No recent congressional trades found for CLGUF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLGUFABBV
Forward yield2336.45%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$42604535760.42M$102.3K
Annual income after 10y$39,296,041,752,408,910.00$24,771.77
Total dividends collected$42372331583.64M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CLGUF vs ABBV ($10,000, DRIP)

YearCLGUF PortfolioCLGUF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$244,345$233,644.86$11,550$430.00+$232.8KCLGUF
2$5,596,956$5,335,506.59$13,472$627.96+$5.58MCLGUF
3$120,208,317$114,219,574.14$15,906$926.08+$120.19MCLGUF
4$2,421,281,629$2,292,658,729.92$19,071$1,382.55+$2421.26MCLGUF
5$45,749,279,790$43,158,508,447.52$23,302$2,095.81+$45749.26MCLGUF
6$811,068,650,211$762,116,920,835.57$29,150$3,237.93+$811068.62MCLGUF
7$13,495,163,269,967$12,627,319,814,241.27$37,536$5,121.41+$13495163.23MCLGUF
8$210,797,521,966,679$196,357,697,267,814.40$50,079$8,338.38+$210797521.92MCLGUF
9$3,092,050,474,774,347$2,866,497,126,269,999.50$69,753$14,065.80+$3092050474.70MCLGUF
10$42,604,535,760,417,464$39,296,041,752,408,910.00$102,337$24,771.77+$42604535760.32MCLGUF

CLGUF vs ABBV: Complete Analysis 2026

CLGUFStock

Cloud Nine Web3 Technologies Inc. operates as a technology company. It focuses on incorporating various technologies into its current platforms leveraging Web 3.0. Web 3.0 enables a future where decentralized users and machines interact with data, value, and other counterparties through a substrate of peer-to-peer networks without the need for third parties. Cloud Nine Web3 Technologies Inc. has a strategic partnership with Next Decentrum Technologies Inc. The company was incorporated in 2015 and is headquartered in Vancouver, Canada.

Full CLGUF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CLGUF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLGUF vs SCHDCLGUF vs JEPICLGUF vs OCLGUF vs KOCLGUF vs MAINCLGUF vs JNJCLGUF vs MRKCLGUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.